Quantcast

Latest Olaparib Stories

2014-10-23 12:30:32

St. Jude Children's Research Hospital researchers have identified a promising new triple-drug combination therapy that exploits DNA repair problem in Ewing sarcoma tumors; clinical trials expected to open soon MEMPHIS, Tenn., Oct. 23, 2014 /PRNewswire-USNewswire/ -- Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St....

2014-10-08 12:25:30

Sales of Breast Cancer Therapies are Expected to Almost Double Through 2023, Fueled by Growth in Several Distinct Market Segments, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that by 2023 an increasing incident population, continued uptake of current premium-priced drugs and the launch of several novel therapies for which large numbers of patients will be eligible, will fuel the breast cancer market to grow...

2014-07-02 08:24:16

LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: AstraZeneca PLC - Product Pipeline Review - 2014 http://www.reportbuyer.com/computing_electronics/manufacturing/astrazeneca_plc_product_pipeline_review_2013.html AstraZeneca PLC - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AstraZeneca PLC - Product Pipeline Review - 2014', provides an overview of the AstraZeneca PLC's pharmaceutical research and development focus....

2014-06-05 12:28:09

Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S. Payers for Formulary Inclusion, According to a New Report from Decision Resources Group BURLINGTON, Mass., June 5, 2014 /PRNewswire/ -- Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key...

2014-05-16 12:27:57

RnRMarketResearch.com adds "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies" to its store. DALLAS, May 16, 2014 /PRNewswire-iReach/ -- "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately...

2014-05-07 23:00:23

ResearchMoz.us include new market research report "Ovarian Cancer Therapeutics to 2020" to its huge collection of research reports. Get Detail Report With TOC at http://www.researchmoz.us/ovarian-cancer-therapeutics-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-survival-and-targeted-therapies-report.html. Albany, New York (PRWEB) May 08, 2014 Researchmoz presents this most up-to-date research on "Ovarian Cancer Therapeutics to 2020 - Late-Stage Pipeline...

2012-11-13 12:15:34

-PI3-kinase inhibitors sensitized tumors to PARP inhibitors. -Combination significantly prolonged progression-free survival in mouse model. The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer, according to results of two studies published in the November issue of Cancer Discovery, a journal of the American Association for Cancer Research. Triple-negative breast cancers...

2012-03-29 02:27:15

Researchers identify genetic markers of drug sensitivity in cancer cells In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The team uncovered hundreds of associations between mutations in cancer genes and sensitivity to anticancer drugs. One of the key responses the team found was that cells from a childhood bone cancer, Ewing's sarcoma, respond to a drug that is...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related